Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis.
作者信息
Taylor J, Mactier R A, Stewart W K, Henderson I S
机构信息
Renal Unit, Ninewells Hospital and Medical School, Dundee.
出版信息
BMJ. 1990 Sep 8;301(6750):476-7. doi: 10.1136/bmj.301.6750.476.
Abstract
摘要
相似文献
1
Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis.促红细胞生成素对接受血液透析的骨髓瘤患者贫血的影响。
BMJ. 1990 Sep 8;301(6750):476-7. doi: 10.1136/bmj.301.6750.476.
2
Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.重组促红细胞生成素在一名血液透析患者多发性骨髓瘤相关性贫血治疗中的应用
Nephrol Dial Transplant. 1994;9(7):876-7.
3
Erythropoietin (r-HuEPO) for the treatment of anaemia in patients with multiple myeloma and end-stage renal failure.促红细胞生成素（重组人促红细胞生成素）用于治疗多发性骨髓瘤和终末期肾衰竭患者的贫血。
Nephrol Dial Transplant. 1995 Dec;10(12):2374-5. doi: 10.1093/ndt/10.12.2374b.
4
[Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].重组人促红细胞生成素治疗合并肾衰竭的多发性骨髓瘤贫血
An Med Interna. 1995 Apr;12(4):187-8.
5
Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis?促红细胞生成素治疗对接受血液透析的骨髓瘤患者是否安全有效？
Clin Nephrol. 1993 Sep;40(3):176-8.
6
Practical guidelines for the use of NESP in treating renal anaemia.
Nephrol Dial Transplant. 2001;16 Suppl 3:22-8. doi: 10.1093/ndt/16.suppl_3.22.
7
8
Effects of withdrawing erythropoietin.停用促红细胞生成素的影响。
BMJ. 1991 Feb 2;302(6771):272-3. doi: 10.1136/bmj.302.6771.272-a.
9
Association between haemoglobin and neopterin concentrations in haemodialysis patients treated with erythropoietin.接受促红细胞生成素治疗的血液透析患者血红蛋白与新蝶呤浓度之间的关联。
Eur J Haematol. 1993 Sep;51(3):175-6. doi: 10.1111/j.1600-0609.1993.tb00621.x.
10
Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
Czech Med. 1990;13(2-3):98-106.
引用本文的文献
1
Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.促红细胞生成素：关于其在慢性肾衰竭中的应用及其对生活质量影响的药物经济学综述。
Pharmacoeconomics. 1993 Jan;3(1):45-82. doi: 10.2165/00019053-199303010-00006.
2
Increased plasma viscosity as a reason for inappropriate erythropoietin formation.
J Clin Invest. 1993 Jan;91(1):251-6. doi: 10.1172/JCI116178.
3
Nephrology, dialysis and transplantation.肾脏病学、透析与移植
Postgrad Med J. 1993 Jul;69(813):516-46. doi: 10.1136/pgmj.69.813.516.
4
The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.重组人促红细胞生成素治疗对小鼠肿瘤放射敏感性及癌性贫血的影响。
Br J Cancer. 1993 Oct;68(4):720-6. doi: 10.1038/bjc.1993.417.
5
Effect of erythropoietin in patients with myeloma.促红细胞生成素对骨髓瘤患者的影响。
BMJ. 1990 Sep 29;301(6753):667. doi: 10.1136/bmj.301.6753.667-a.
本文引用的文献
1
Anaemia in patients with myelomatosis.骨髓瘤患者的贫血
Br J Cancer. 1982 Jun;45(6):887-94. doi: 10.1038/bjc.1982.141.
2
Identification of tissues and cells producing erythropoietin in the anemic mouse.
Contrib Nephrol. 1988;66:17-24. doi: 10.1159/000416000.
3
Dialysis in the management of the renal failure of myeloma.透析在骨髓瘤肾衰竭管理中的应用
Q J Med. 1989 Oct;73(270):871-2.
Zotero 插件